Your browser doesn't support javascript.
loading
Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD.
Habib, Mohammed; Buisson, Marlyse; Lupo, Julien; Agbalika, Felix; Socié, Gérard; Germi, Raphaele; Baccard, Monique; Imbert-Marcille, Berthe-Marie; Dantal, Jacques; Morand, Patrice; Drouet, Emmanuel.
Afiliação
  • Habib M; Institut de Biologie Structurale (IBS), Université Grenoble Alpes, CEA, CNRS, Grenoble, France.
  • Buisson M; Institut de Biologie Structurale (IBS), Université Grenoble Alpes, CEA, CNRS, Grenoble, France.
  • Lupo J; Unit of Virology, University, Hospital, Université Grenoble Alpes, Grenoble, France.
  • Agbalika F; Unit of Virology, University, Hospital, Université Grenoble Alpes, Grenoble, France.
  • Socié G; Unit of Virology, Hôpital Saint-Louis, AP-HP, Université Paris-Diderot, Paris, France.
  • Germi R; Unit of Clinical Hematology, Hôpital Saint-Louis, AP-HP, Université Paris-Diderot, Paris, France.
  • Baccard M; Unit of Virology, University, Hospital, Université Grenoble Alpes, Grenoble, France.
  • Imbert-Marcille BM; Unit of Virology, University, Hospital, Université Grenoble Alpes, Grenoble, France.
  • Dantal J; Unit of Virology, University Hospital, Université de Nantes, Nantes, France.
  • Morand P; Unit of Nephrology & Clinical Immunology, University Hospital, Université de Nantes, Nantes, France.
  • Drouet E; Unit of Virology, University, Hospital, Université Grenoble Alpes, Grenoble, France.
Sci Rep ; 7(1): 10479, 2017 09 05.
Article em En | MEDLINE | ID: mdl-28874674
The ZEBRA protein (encoded by the BZLF1 gene), is the major transcription factor of EBV, expressed upon EBV lytic cycle activation. Several studies highlighted the critical role of EBV lytic infection as a risk factor for lymphoproliferative disorders like post-transplant lymphoproliferative disease (PTLD). Here, we use an antigen-capture ELISA assay specifically designed to detecting the circulating soluble ZEBRA (sZEBRA) in serum samples (threshold value determined at 40ng/mL). We retrospectively investigated a population of 66 transplanted patients comprising 35 PTLD. All the samples from a control population (30 EBV-seronegative subjects and 25 immunocompetent individuals with EBV serological reactivation), classified as sZEBRA < 40ng/mL were assigned as negative. At PTLD diagnosis, EBV genome (quantified by qPCR with EBV DNA>200 copies/mL) and sZEBRA were detectable in 51% and 60% of cases, respectively. In the patients who developed a pathologically-confirmed PTLD, the mean sZEBRA value in cases, was 399 ng/mL +/- 141 versus 53ng/mL +/- 7 in patients who did not (p < 0,001). This is the first report relating to the detection of the circulating ZEBRA in serum specimens, as well as the first analysis dealing with the lytic cycle of EBV in PTLD patients with this new biomarker.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transativadores / Transplante de Rim / Transplante de Pulmão / Infecções por Vírus Epstein-Barr / Transtornos Linfoproliferativos Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transativadores / Transplante de Rim / Transplante de Pulmão / Infecções por Vírus Epstein-Barr / Transtornos Linfoproliferativos Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article